Ang mga impurities ng amino acid na ginagamit para sa synthesize protein
Detalye ng produkto
| NO | Mga produkto | Cas no | Pangunahing tagapagpahiwatig ng kalidad | |||
| Kadalisayan | Max. karumihan | Kabuuang nalalabi na nalalabi | Kahalumigmigan | |||
| 1 | FMOC-β-ALA-ALA-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 2 | FMOC-D-ALA-D-ALA-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 3 | FMOC-β-ALA-D-ALA-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 4 | FMOC-ARG (PBF) -Arg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 5 | FMOC-β-ALA-ARG (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 6 | FMOC-D-ARG (PBF) -D-ARG (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 7 | FMOC-β-ALA-D-ARG (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 8 | Fmoc-homoarg (pbf) -homoarg (pbf) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 9 | FMOC-β-ALA-HOMOARG (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 10 | Fmoc-asn (trt) -asn (trt) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 11 | FMOC-β-ALA-ASN (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 12 | Fmoc-asp (otbu) -asp (otbu) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 13 | FMOC-β-ALA-APP (OTBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 14 | FMOC-CYS (TRT) -CYS (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 15 | FMOC-β-ALA-CYS (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 16 | FMOC-CYS (ACM) -CYS (ACM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 17 | FMOC-β-ALA-CYS (ACM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 18 | Fmoc-gln (trt) -gln (trt) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 19 | FMOC-β-ALA-GLN (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 20 | Fmoc-glu (otbu) -glu (otbu) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 21 | FMOC-β-ALA-GLU (OTBU) -OH.H2O | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 22 | FMOC-β-ALA-GLY-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 23 | Fmoc-his (trt) -His (trt) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 24 | FMOC-β-ALA-HIS (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 25 | Fmoc-Ile-Ile-Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 26 | FMOC-β-ALA-ILE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 27 | Fmoc-leu-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 28 | FMOC-β-ALA-LEU-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 29 | Fmoc-d-leu-d-leu-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 30 | FMOC-β-ALA-D-LEU-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 31 | Fmoc-lys (boc) -lys (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 32 | FMOC-β-ALA-LYS (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 33 | Fmoc-lys (alloc) -lys (alloc) -oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 34 | FMOC-β-ALA-LYS (ALLOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 35 | FMOC-Met-Met-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 36 | FMOC-β-ALA-MET-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 37 | Fmoc-orn (BOC) -orn (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 38 | Fmoc-β-ala-orn (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 39 | Fmoc-phe-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 40 | FMOC-β-ALA-PHE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 41 | Fmoc-d-phe-d-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 42 | FMOC-β-ALA-D-PHE-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 43 | Fmoc-pro-pro-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 44 | FMOC-β-ALA-Pro-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 45 | Fmoc-ser (tbu) -ser (tbu) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 46 | FMOC-β-ALA-SER (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 47 | FMOC-SER (TRT) -SER (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 48 | FMOC-β-ALA-SER (TRT) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 49 | Fmoc-thr (tbu) -thr (tbu) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 50 | FMOC-β-ALA-THR (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 51 | FMOC-TRP (BOC) -TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 52 | FMOC-β-ALA-TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 53 | FMOC-D-TRP (BOC) -D-TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 54 | FMOC-β-ALA-D-TRP (BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 55 | Fmoc-tyr (tbu) -tyr (tbu) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 56 | FMOC-β-ALA-TYR (TBU) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 57 | Fmoc-d-tyr (ET) -D-tyr (ET) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 58 | FMOC-β-ALA-D-TYR (ET) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 59 | Fmoc-tyr (ako) -tyr (ako) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 60 | FMOC-β-ALA-TYR (ME) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 61 | Fmoc-val-val-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 62 | FMOC-β-ALA-VAL-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 63 | FMOC-D-CIT-D-CIT-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 64 | FMOC-β-ALA-D-CIT-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 65 | FMOC-β-ALA-DAB-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 66 | Fmoc- (3- (2-naphthyl) -d-ala) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 67 | FMOC-β-ALA-3- (2-naphthyl) -D-ALA-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 68 | FMOC- (3- (3-pyridinyl) -D-ALA) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 69 | FMOC-β-ALA-3- (3-pyridinyl) -D-ALA-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 70 | Fmoc- (4-chloro-d-phe) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 71 | FMOC-β-ALA-4-chloro-d-phe-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 72 | FMOC- (D-4APH (TBUCBM)) 2-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 73 | FMOC-β-ALA-D-4APH (TBUCBM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 74 | Fmoc-aph (l-hor) -aph (l-hor) -Oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 75 | FMOC-β-ALA-APH (L-HOR) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 76 | Fmoc-lys (IPR, BOC) -LYS (IPR, BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 77 | FMOC-β-ALA-LYS (IPR, BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 78 | FMOC-β-ALA-AEEA-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 79 | FMOC-AIB-AIB-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 80 | FMOC-β-ALA-AIB-OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 81 | Fmoc-arg-oh | 91000-69-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 82 | H-ARG (PBF) -OH | 200115-86-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 83 | Fmoc-d-arg-oh | 130752-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 84 | HD-ARG (PBF) -OH | 200116-81-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 85 | Fmoc-homoarg-oh.hcl | 208174-14-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 86 | H-homoarg (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 87 | Fmoc-d-homoarg-oh | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 88 | HD-HOMOARG (PBF) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 89 | Fmoc-asn-oh | 71989-16-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 90 | H-ASN (TRT) -OH | 132388-58-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 91 | Fmoc-asp-oh | 119062-05-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 92 | H-asp (OTBU) -OH | 3057-74-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 93 | Fmoc-cys-oh | 135248-89-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 94 | H-cys (TRT) -OH | 2799/7/7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 95 | H-cys (ACM) -OH.HCl | 28798-28-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 96 | Fmoc-gln-oh | 71989-20-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 97 | H-gln (trt) -Oh | 102747-84-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 98 | Fmoc-glu-oh | 121343-82-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 99 | H-glu (otbu) -Oh.h2o | 2419-56-9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 100 | Fmoc-his-oh | 116611-64-4 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 101 | H-his (trt) -oh | 35146-32-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 102 | Boc-his-oh | 17791-52-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 103 | Fmoc-lys-oh | 105047-45-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 104 | H-lys (BOC) -OH | 2418-95-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 105 | H-lys (Alloc) -OH | 6298/3/9 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 106 | Fmoc-orn-oh.hcl | 201046-57-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 107 | H-ORM (BOC) -OH | 13650-49-2 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 108 | Fmoc-ser-oh | 73724-45-5 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 109 | H-Ser (TBU) -OH | 18822-58-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 110 | H-ser (trt) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 111 | Fmoc-thr-oh.h2o | 73731-37-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 112 | H-thr (tbu) -Oh | 4378-13-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 113 | FMOC-TRP-OH | 35737-15-6 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 114 | H-TRP (BOC) -OH | 146645-63-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 115 | FMOC-D-TRP-OH | 86123-11-7 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 116 | HD-TRP (BOC) -OH | 201290-11-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 117 | Fmoc-tyr-oh | 92954-90-0 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 118 | H-tyr (tbu) -Oh | 18822-59-8 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 119 | Fmoc-d-tyr-oh | 112883-29-1 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 120 | HD-Tyr (ET) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 121 | H-tyr (ako) -OH.HCl | 67423-44-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 122 | FMOC-D-4APH (CBM) -OH | 324017-22-3 | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 123 | HD-4aph (TBUCBM) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 124 | Fmoc-lys (IPR) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
| 125 | H-lys (IPR, BOC) -OH | NA | ≥98.0% | ≤1.0% | ≤8.0% | ≤2.0% |
Tungkol sa
Kabayaran
Ang Gentolex ay nagbibigay ng mahusay na kalidad ng mga produkto, kung ang anumang kalidad ng produkto ay itinaas ng kliyente sa loob ng kinakailangang oras ng oras na may sapat na mga ebidensya, magbibigay kami ng kinakailangang pagsusuri at pagsusuri upang ma -trigger ang mga pamamaraan ng mga kabayaran.
Produksiyon
Ang mga kapasidad ng mga produktong parmasyutiko ay umabot sa grade ng tonelada, ang mga kapasidad ng mga produktong kemikal ay umaabot sa 100tons+ grade, ang mga kakayahan ay mahusay na kagamitan upang maghatid ng mga kliyente sa buong mundo.
Pananaliksik at Pag -unlad
Bawat taon, mayroong plano na itinakda ng koponan ng R&D upang makabuo ng iba't ibang mga bagong produkto, kapag ang mga target na itinakda, ang bawat miyembro sa koponan ay kailangang magpatuloy sa responsibilidad ng KPI at may patakaran sa insentibo.
